At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
Flortaucipir F18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multicenter Study Evaluating the Imaging Characteristics of a Follow up 18F-AV-1451 Scan in Subjects That Participated in the Confirmatory Cohort of 18F-AV-1451-A05
In Brief
A Phase 2 clinical trial evaluating Flortaucipir F18 and PET Scan for Alzheimer's Disease. Completed, enrolled 79 participants across 22 sites.
Detailed Summary
This study will evaluate longitudinal change of tau deposition as measured by flortaucipir F 18 uptake over time.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartAug 2016
Primary CompletionAug 2017
TodayJul 2026
First PostedJun 10, 2016
Enrollment StartAug 1, 2016
Primary CompletionAug 28, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.1 years ago
Interventions
Flortaucipir F18drug
370 megabecquerel (MBq) IV single-dose
PET Scanprocedure
positron emission tomography (PET) scan